Drugs Contributing to Anticholinergic Burden and Risk of Fall or Fall-Related Injury among Older Adults with Mild Cognitive Impairment, Dementia and Multiple Chronic Conditions: A Retrospective Cohort Study
It is not known whether drugs with different anticholinergic ratings contribute proportionately to overall anticholinergic score.
Our objective was to assess the risk of falls or fall-related injuries as a function of the overall anticholinergic score resulting from drugs with different anticholinergic ratings among people with impaired cognition.
This was a retrospective cohort study of adults aged ≥ 65 years with mild cognitive impairment (MCI) or dementia and two or more additional chronic conditions (N = 10,698) in an integrated delivery system. Electronic health record data, including pharmacy fills and diagnosis claims, were used to assess anticholinergic medication use, quantified using the anticholinergic cognitive burden (ACB) scale, falls and fall-related injuries.
During a median follow-up of 366 days, 63% of the cohort used one or more ACB drug; 2015 (18.8%) people experienced a fall or fall-related injury. Among patients with a daily ACB score of 5, the greatest increase in risk of falls or fall-related injuries was seen when level 2 and level 3 drugs were used in combination [hazard ratio (HR) 2.06; 95% confidence interval (CI) 1.51–2.83]. Multiple ACB level 1 drugs taken together also increased the hazard of a fall or fall-related injury (HR 1.16; 95% CI 1.03–1.32). The risk of fall or fall-related injury as a function of exposure to ACB level 2 drugs (HR 1.56; 95% CI 1.16–2.10) was higher than that for ACB level 1 or 3 drugs.
The same daily ACB score was associated with a different degree of risk, depending on the ACB ratings of the individual drugs comprising the score. Combinations of level 2 and level 3 drugs had the greatest risk of fall or fall-related injury relative to other individuals with the same daily ACB score. Low-potency anticholinergic drugs taken together modestly increased the hazard of a fall or fall-related injury.
This study was supported by R24AG045050-03S2 from the National Institute on Aging. Support was provided by the KPCO Pharmacy Department for Linda Weffald’s time. Dr. Boyd’s time was in part supported by 1K24AG056578-01 from the National Institute on Aging. Dr. Green is supported by K23AG054742.
Compliance with Ethical Standards
Conflict of Interest
Ariel Green, Liza Reifler, Elizabeth Bayliss, Linda A. Weffald have no conflicts of interest that are directly relevant to the content of this study. Cynthia Boyd writes a chapter on multimorbidity for UpToDate, for which she receives a royalty.
- 13.Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.Google Scholar
- 14.Agency for Healthcare Research and Quality. Chronic condition classification. http://www.icpsr.umich.edu/icpsrweb/content/AHRQMCC/shared-code.html. Accessed 14 Aug 2017.
- 16.Campbell NL, Maidment I, Fox C, Khan B, Boustani M. The 2012 update to the anticholinergic cognitive burden scale. J Am Geriatr Soc. 2013;61(S1):S142–3.Google Scholar
- 23.Alvarez CA, Mortensen EM, Makris UE, Berlowitz DR, Copeland LA, Good CB, et al. Association of skeletal muscle relaxers and antihistamines on mortality, hospitalizations, and emergency department visits in elderly patients: a nationwide retrospective cohort study. BMC Geriatr. 2015;15(1):2.CrossRefGoogle Scholar
- 30.Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862–70.CrossRefGoogle Scholar